{
Novartis AG

Companies

}
001122334455554433221100
001122334455554433221100

light horse therapeutics secures 62 million and partners with novartis

Light Horse Therapeutics has secured $62 million in Series A financing and formed a partnership with Novartis, which includes a $25 million upfront payment and potential milestone payments of up to $1 billion. The biotech aims to revolutionize drug discovery with its genetic editing-based platform, initially focusing on challenging oncology targets while exploring other therapeutic areas in the future.
Yahoo Finance
United States Dollar Bristol-Myers Squibb Co Novartis AG ABBVIE ARE USA John Tallarico Markus Renschler Show more
Finance & Economy, Press Release
13:38 10.01.2025

light horse therapeutics launched with 62 million funding and novartis partnership

Light Horse Therapeutics has launched with $62 million in Series A financing led by Versant Ventures, alongside partners including Novartis. The company focuses on developing small molecule therapeutics using a precision gene editing platform to tackle challenging oncology targets, with potential for broader applications. The collaboration with Novartis includes a $25 million upfront payment and up to $1 billion in milestone payments, aiming to create first-in-class therapies.
World Pharmaceutical Frontiers
United States Dollar Bristol-Myers Squibb Co Novartis AG ABBVIE ARE JPN USA Ben Cravatt Brian Liau Markus Renschler John Tallarico Nathanael Gray Show more
Healthcare, Press Release
13:38 10.01.2025

global cancer immunotherapy market projected to reach 236.9 billion by 2030

The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
GlobeNewswire News Room
United States Dollar GSK plc Bristol-Myers Squibb Company Bayer AG Eli Lilly and Company Pfizer Inc. Merck & Co., Inc. Novartis AG Immunocore Holdings plc AstraZeneca PLC Amgen Inc. F. Hoffmann-La Roche Ltd. IND FRA ARG CAN ESP USA BRA CHN MEX DEU ITA JPN GBR KOR Show more
Healthcare, Market Report
10:06 10.01.2025

dry eye disease market growth trends and competitive landscape analysis 2025 to 2032

The Dry Eye Disease market is experiencing significant growth, driven by increased product demand and technological advancements. A comprehensive report analyzes market size, trends, competitive landscape, and future growth prospects, highlighting key players like Novartis AG and Alcon Inc. It also delves into consumption patterns, pricing strategies, and market segmentation across various applications and regions.
openPR.com
Novartis AG Alcon Inc. SUN Pharmaceutical Industries Ltd. Alice Mutum Viju Shah Show more
Healthcare, Market Report
07:17 10.01.2025

light horse therapeutics partners with novartis for innovative cancer drug development

Light Horse Therapeutics has entered a strategic collaboration with Novartis, securing a $25 million upfront payment and the potential for up to $1 billion in milestone payments for research, development, and sales. This partnership aims to leverage Light Horse's innovative platform to develop first-in-class therapeutics, particularly targeting challenging oncology areas. The collaboration is expected to accelerate the creation of novel cancer treatments, utilizing advanced genetic screening and proprietary chemical libraries.
BioSpace
Novartis AG John Tallarico Markus Renschler
Technology & Innovation, Press Release
16:15 09.01.2025

light horse therapeutics secures funding and partnership with novartis

Light Horse Therapeutics has launched with a $62-million series A financing and a collaboration with Novartis potentially worth over $1 billion. The San Diego-based biotech employs a "function-first" approach to drug discovery, focusing initially on oncology targets while integrating precision genome editing techniques. The partnership includes a $25-million upfront payment and opportunities for significant R&D and sales milestones.
firstwordpharma.com
United States Dollar Bristol-Myers Squibb Co Novartis AG ABBVIE USA Ben Cravatt Laure Escoubet Brian Liau Markus Renschler John Tallarico Nathanael Gray Show more
Technology & Innovation, News Article
16:13 09.01.2025

global keratoconus treatment market analysis growth outlook and key players

The global Keratoconus Treatment market, valued at US$ 0.5 billion in 2022, is projected to grow to US$ 0.6 billion by 2031, with a CAGR of 3.9% from 2024 to 2031. Key players include Sandoz International GmbH, HOYA, and Menicon Co., Ltd., focusing on various treatment options like corrective lenses and corneal surgeries. Recent developments highlight Menicon's launch of the ROSE K hard contact lens in China, tailored for keratoconus patients.
openPR.com
Bausch Health Companies Inc. Menicon Co., Ltd. Seed Co. Ltd. Johnson & Johnson Services Inc. The Cooper Companies, Inc. Novartis AG Hoya Corp Carl Zeiss Meditec AG FRA ARG ARE CAN SAU USA RUS IND AUS GBR BHR ITA OMN KWT BRA QAT COL DEU CHN MEX ISR JPN Show more
Healthcare, Market Report
14:48 09.01.2025

novartis reports strong earnings but faces analyst downgrades and stock challenges

Novartis AG reported a net margin of 35.96% and a return on equity of 34.80%, with quarterly revenue of $12.82 billion, surpassing expectations. The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.94. Analysts forecast an average EPS of 7.65 for the current year, while the stock currently holds a "Reduce" rating among analysts.
MarketBeat
Novartis AG CHE
Finance & Economy, Market Report
10:04 09.01.2025

legal notice halts novartis share transfer to radiant pharmaceuticals in bangladesh

Legal notices have been issued to the governor of Bangladesh Bank and other officials to halt the transfer of Taka 230 crore worth of Novartis Bangladesh shares to Radiant Pharmaceuticals Limited. The notices highlight concerns over potential violations of the Money Laundering Prevention Act, as the sale process, initially approved under Salman F Rahman, is now being advanced by Naser Shahriar Jahedi Mohul, who is linked to the business interests of Sheikh Hasina's family.
BSS
Novartis AG BGD Salman F Rahman Sheikh Hasina
Regulatory & Legal, News Article
13:19 08.01.2025

congestive heart failure market poised for significant growth by 2034

The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
Barchart.com
United States Dollar Mesoblast Ltd Eli Lilly and Co Boehringer Ingelheim KG Bayer AG Merck & Co., Inc. Bristol-Myers Squibb Co Intra-Cellular Therapies, Inc. BioCardia, Inc. Novo Nordisk A/S scPharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. Cytokinetics, Incorporated Novartis AG Tenax Therapeutics, Inc. AstraZeneca PLC Amgen Inc. Otsuka Pharmaceutical Co. Ltd. FRA DEU ITA JPN GBR USA Show more
Healthcare, Market Report
15:50 07.01.2025
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.